Speakers for UBD-Snibe 2026

Speakers

You are here

Accommodation

Details available soon

Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality worldwide, despite major advances in therapeutics and clinical care. Achieving meaningful progress in prevention and early diagnosis now requires a paradigm shift in how diagnostics are conceived, delivered, and integrated into care pathways. Laboratory medicine is evolving from a test-centric discipline toward an integrated diagnostic system embedded across prevention, primary care, and specialized services. High-value biomarkers such as natriuretic peptides, cardiac troponins, and emerging multimarker strategies enable earlier identification of subclinical disease, refined risk stratification, and longitudinal monitoring of patients at risk. Recent translational work illustrates how repurposed and novel biomarkers, including CA125, can complement NT-proBNP in heart failure, improving prognostic assessment and supporting therapeutic monitoring.

At the same time, emerging technologies are reshaping the diagnostic landscape. When combined with digital connectivity and artificial intelligence, laboratory data become part of continuous, learning healthcare systems, supporting predictive analytics, clinical decision support, and population-level prevention strategies. Crucially, this transformation elevates the role of specialists in laboratory medicine. Their expertise is essential to ensure analytical quality, clinical relevance, harmonization across settings, and responsible implementation of AI-driven tools. As diagnostics become distributed, laboratory professionals increasingly act as architects of diagnostic ecosystems, integrating data, guiding interpretation, and safeguarding equity and trust.

Drawing on recent clinical validation studies, system-level perspectives, and emerging technology frameworks, this talk highlights how laboratories can move upstream in cardiovascular care, shifting from reactive testing to proactive prevention. Ultimately, leveraging biomarkers, digital health, and intelligent diagnostics offers a unique opportunity to reduce diagnostic delays, personalize interventions, and improve cardiovascular outcomes at scale. I truly believe that clinical laboratories are not supporting actors in this transformation, they are key drivers of the future of cardiovascular disease prevention and early diagnosis.